In the World Health Organization classification, fibroblast growth factor receptor 1 (FGFR1)-rearranged myeloid and lymphoid neoplasms are included with rearrangements involving plateletderived growth factor receptor α and β.
1 FGFR1-rearranged neoplasms are acquired hematopoietic stem cell disorders that usually present as an eosinophilia-associated myeloproliferative neoplasm, acute leukemia and/or lymphoblastic lymphoma. 1, 2 Among the 15 different FGFR1 fusion partners that have been identified, translocations involving BCR-FGFR1 t(8;22)(p11;q11) have a distinct phenotype mimicking chronic myelogenous leukemia with a predilection toward development of B lymphoblastic lymphoma, mixed-phenotype B/myeloid acute leukemias, [3] [4] [5] [6] or even trilineage T/B/myeloid mixed-phenotype acute leukemias. 7 The acute leukemias/lymphomas associated with BCR-FGFR1 demonstrate an aggressive course and poor prognosis, with no documented cases of complete remission after chemotherapy. Allogeneic hematopoietic stem cell transplantation (HSCT) is recommended for these patients. 2, 5, 7, 8 FGFR1 tyrosine kinase inhibition represents a promising therapy for neoplasms possessing FGFR1 rearrangements. Ponatinib is a third-generation tyrosine kinase inhibitor that was approved for patients with resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. In addition to targeting BCR-ABL1, ponatinib also exhibits high affinity for FGFR1. 9, 10 We present here the first use of ponatinib in a patient with an FGFR1-rearranged neoplasm manifesting as a BCR-FGFR1-positive trilineage mixed-phenotype acute leukemia.
In June 2013, a previously healthy 47-year-old male presented to the emergency department with 2 weeks of enlarging cervical lymphadenopathy, trismus and odynophagia. Physical examination revealed bilateral tonsillar enlargement, bulky bilateral cervical lymphadenopathy, mild bilateral axillary lymphadenopathy and mild splenomegaly. The total leukocyte count was 132 × 10 9 /l, hemoglobin 11.1 g/dl and platelet count 117 × 10 9 /l. The differential revealed 36% segmented and band neutrophils, 9% lymphocytes, 4% monocytes, 8% metamyelocytes, 1% myelocytes and 42% blasts. No eosinophilia or basophilia was observed. Computed tomography of the chest showed an 8-cm mediastinal mass.
The bone marrow aspirate was aspiculate with a similar composition to the peripheral blood. The core biopsy was hypercellular for age (100%). Blasts comprised~80-90% of nucleated cells and exhibited varied size and morphology including fine chromatin, nuclear folding and abundant cytoplasm, with a subset of leukemic cells possessing Auer rods (Supplementary Figures 1A-C Figure 1D) . A BCR-ABL1 fusion probe analysis demonstrated an abnormal signal pattern with four BCR signals (Supplementary Figure 1E , green probe), with arrows indicating one BCR signal localizing to the der(8)t (8;22) . In addition, a FGFR1 break-apart probe (Cytocell, Cambridge, MA, USA) showed separation of one of the probes iñ 95% of cells indicating an FGFR1 gene rearrangement (Supplementary Figure 1F) . Flow cytometry on the aspirate (Supplementary Figures 1G-L) showed three separate clonal populations: (1) the majority of blasts were myeloid, with expression of CD11c, CD13, CD14 (subset), CD15 (partial), CD33, CD34 (variable), CD64 and myeloperoxidase; (2) the T-lymphoblast subset (10-15%) expressed cytoplasmic CD3, CD2, CD5 (dim partial) and CD7 (dim partial); and (3) the B-lymphoblast subset (20%) expressed CD19, CD10, cytoplasmic CD79a, CD22 (dim) and TdT. T-cell clonality by PCR was negative and B-cell clonality showed an IGH gene rearrangement. Morphologic and flow cytometric assessment of the cerebrospinal fluid was negative.
PCR of genomic DNA (gDNA) identified the breakpoint in the BCR and FGFR1 genes at a four-nucleotide fragment (GCCA) shared by the intron between exon 4 and exon 5 of BCR and the intron between exon 8 and exon 9 of FGFR1 ( Figure 1a ). Reversetranscription PCR confirmed that this gene fusion resulted in an in-frame fusion transcript between BCR exon 4 and FGFR1 exon 9 ( Figure 1b) . The reciprocal FGFR1-BCR fusion gene and transcript were also detected (data not shown). A custom-nested quantitative real-time PCR (qPCR) assay was used to detect and quantify gene fusion allele burden from gDNA at diagnosis and throughout therapy with a sensitivity of detection of 1 in 10 000 (Supplementary Figure 2 and data not shown). Methods and primers sets are described in the Supplementary Information and Supplementary Table 1 .
The patient underwent initial treatment with prednisone and hydroxyurea. Despite initial cytoreduction with 3 days of cyclophosphamide 300 mg/m 2 daily and dexamethasone, there was no change in lymphadenopathy or total leukocyte count. He subsequently underwent induction chemotherapy with a 5-day course of mitoxantrone, etoposide and cytarabine (MEC). A bone marrow biopsy on day 12 of MEC treatment showed no morphologic evidence of disease in a hypocellular marrow. However, the patient developed clinical progression with rapid worsening of his cervical lymphadenopathy. Positron emission tomography (PET)-computed tomography imaging on day 13 of MEC demonstrated cervical and mediastinal adenopathy as well as a paravertebral soft tissue mass (Figures 2a-c) . Fine needle aspiration of the cervical lymphadenopathy was non-diagnostic.
On the basis of encouraging preclinical data in myeloid neoplasms with FGFR1-rearranged tumors, 9,10 we commenced treatment with single-agent ponatinib 45 mg daily on day 14 after the initiation of MEC. The drug was administered on an off-label basis given the worsening lymphadenopathy and urgent need in this case. Treatment was well tolerated, with only a grade 1 headache that was possibly related to ponatinib. Within 2 weeks of initiating ponatinib, the patient experienced marked reduction in cervical lymphadenopathy with improved neck pain and mobility, as well as resolution of his trismus. PET imaging performed 4 weeks after start of ponatinib monotherapy confirmed moderate improvement in cervical lymphadenopathy and complete resolution of his mediastinal disease and paravertebral mass (Figures 2d-f) .
A repeat bone marrow biopsy at the time of peripheral blood count recovery (4 weeks after the start of ponatinib and 6 weeks after the initiation of MEC) demonstrated residual leukemia with patchy involvement by 15-20% blasts on the core biopsy (compared with 80-90% at diagnosis), with lesser involvement noted on bone marrow aspirate and by flow cytometry (5%). Standard cytogenetics revealed the t(8;22)(p11.2;q11.2) translocation in 3 of 20 (15%) cells, and FISH analysis revealed the FGFR1 rearrangement in 22/200 (11%) cells. Because of residual disease, he underwent repeat induction with high-dose methotrexate and cytarabine (per cycle B of the hyper-CVAD regimen) while continuing ponatinib. This resulted in further improvement in his cervical lymphadenopathy. Twelve weeks after starting ponatinib, his bone marrow showed a complete morphologic remission but standard karyotyping detected the FGFR1 rearrangement in 6/21 metaphases (29%) and in 26/200 cells (13%) by FISH.
The patient subsequently underwent a matched-sibling allogeneic HSCT from his sister with a conditioning regimen of total body irradiation, etoposide and cyclophosphamide with a radiation boost to areas of residual disease in the cervical regions. Ponatinib was discontinued at the time of radiation treatment. Prednisone and tacrolimus were used for graft-versushost disease (GVHD) prophylaxis. Six months following HSCT, a bone marrow biopsy exhibited a complete morphologic remission with a normal donor female karyotype, normal FISH studies and 100% donor chimerism. However, nested qPCR detected the BCR-FGFR1 fusion (8.3% allele burden relative to diagnosis), indicating persistent minimal residual disease (MRD; Figure 1c) . Therefore, ponatinib was reinitiated at 45 mg daily because of concern for overt relapse. After 1.5, 2 and 6.5 months of ponatinib treatment (8.5, 9 and 13.5 months after HSCT; Figure 1c) , the BCR-FGFR1 fusion showed a marked reduction to o 0.2% of the allele burden at diagnosis. Given this result, the decision was made to reduce the dose of ponatinib to 15 mg daily to mitigate potential future toxicity, including arterial or venous thrombosis.
The patient subsequently developed grade 4 increased SGOT and SGPT that was attributed to a flare of GVHD of the liver because it transpired in parallel with tapering of his corticosteroid GVHD prophylaxis. Because drug toxicity could not be excluded, ponatinib was discontinued. Re-institution of corticosteroids led to resolution of the liver function abnormalities. Two months after discontinuation of ponatinib, a repeat bone marrow biopsy showed a persistent complete morphologic and cytogenetic remission with full donor chimerism. However, the BCR-FGFR1 allele burden by qPCR increased to 0.9% of the allele burden at diagnosis (Figure 1c) , prompting the re-initiation of ponatinib 15 mg daily.
Herein, we demonstrate the partial remitting activity of ponatinib in a patient with FGFR1-rearranged trilineage mixedphenotype acute leukemia. Single-agent ponatinib demonstrated substantial reduction of lymphadenopathy that was confirmed by PET imaging. However, with MEC chemotherapy, and subsequent monotherapy with ponatinib, only a partial morphologic and cytogenetic remission of the leukemia was achieved. The subsequent combination of ponatinib with hyper-CVAD led to a complete morphologic remission and maintenance of a major cytogenetic response before the patient proceeded to HSCT. Six months after HSCT, MRD was detected by nested qPCR for BCR-FGFR1. However, with subsequent re-introduction of ponatinib, near MRD negativity was achieved within a short time frame. The reduction in allele burden was likely a direct effect of Figure 2 . Positron emission tomography (PET) imaging before and after single-agent ponatinib. The patient was imaged by PET on day 13 following induction chemotherapy with mitoxantrone, etoposide and cyclophosphamide (a-c). Ponatinib monotherapy was initiated on day 14 and scans were repeated 1 month later (d-f). Representative images of involved cervical regions and a paravertebral mass (white arrow) are shown. Patient consent was given to publish these images.
Letters to the Editor ponatinib as levels of the fusion rose again after a 2-month hiatus from the drug. However, a contribution of a graft-versus-leukemia effect cannot be excluded. In a prior case, donor lymphocyte infusion elicited a molecular remission in a patient with MRD detected by PCR for the ZNF198-FGFR1 fusion.
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The BCR-FGFR1 gene fusion identified here is consistent with those previously observed. 3, 4, 8, 12, 13 Nomenclature inconsistency regarding FGFR1 is due to different splice isoforms, as the FGFR1 exon 9 downstream of the breakpoint is also referred to as exon 10 according to Genbank annotation and exon 10 or 11 according to the UCSC Genome Browser.
Inhibitors of FGFR1 including ponatinib and dovitinib have shown in vitro activity against cells harboring FGFR1 rearrangements. 9, 10, 14 Ponatinib can improve survival in xenotransplanted mice transplanted with a human cell line expressing a chimeric FGFR1 kinase. 10 Only two prior reports have detailed the clinical efficacy of multikinase inhibitors in patients with FGFR1-rearranged neoplasms. In a case of BCR-FGFR1-positive B-cell ALL, the combination of sorafenib plus hydroxyurea resulted in a transient decrease in leukocytosis, but the patient quickly relapsed and died. 6 In another patient, treatment of a ZNF198-FGFR1 fusion-associated myeloproliferative neoplasm with midostaurin (PKC412) elicited some reduction of leukocytosis, lymphadenopathy and splenomegaly, but had no effect on bone marrow histopathology or cytogenetic findings. 15 An unmet need exists for the treatment of the chemotherapyresistant FGFR1-rearranged myeloid and lymphoid malignancies. Chemotherapy or ponatinib alone is likely insufficient to produce in-depth remissions in these patients; therefore, ponatinib combined with chemotherapy as a bridge to allogeneic HSCT, or as a single agent following HSCT to induce or maintain a molecular remission merits further investigation. Although well tolerated in this case, the potential benefits of ponatinib in this rare and aggressive disease need to be weighed against concerns for serious adverse events that have emerged in the setting of CML.
